针对早期症状性阿尔茨海默氏病的抗Aβ抗体治疗的实用脑部MRI指南
相关实验视频
Updated: May 16, 2025
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
71
Shingo Kakeda1, Yukio Miki2, Kohsuke Kudo3
1Department of Radiology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
概括
这些指南支持对接受抗粉样β (Aβ) 抗体治疗的患者进行MRI诊断. 他们专注于诊断与粉样蛋白相关的成像异常 (ARIA) 并确保安全的治疗.
科学领域:
- 神经学 神经学
- 放射学 放射学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对神经疾病的抗粉样β (Aβ) 抗体疗法正在出现.
- 准确的诊断和治疗相关副作用的管理是至关重要的.
- 与粉样蛋白相关的成像异常 (ARIA) 是一个关键问题.
研究的目的:
- 在接受抗Aβ抗体治疗的患者中建立MRI诊断指南.
- 支持,而不是限制基于诊断标准的治疗资格.
- 为管理ARIA提供一个框架.
主要方法:
- 由日本领先的放射学和神经成像学会合作开发.
- 对现有文献和临床试验数据进行全面审查.
- 纳入已建立的设施和医生专业知识标准.
主要成果:
- 指南强调设施标准和医生在ARIA和MRI解释方面的专业知识.
- 建议的知识获取包括ARIA,脑MRI和抗Aβ抗体治疗方案.
- 专注于准确的诊断和ARIA的有效管理.
结论:
- 有助于准确的ARIA诊断和管理.
- 确保安全使用抗Aβ药物.
- 为MRI设施提供框架,包括人员和系统要求.
相关概念视频
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
01:26Alzheimer's Disease: Overview
350
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
350